Evidence‐based recommendations are intended to support clinicians, particularly in primary care, to identify MCI and plan an intervention strategy to help slow age‐related cognitive decline.
Abstract
ABSTRACT Background Mild cognitive impairment (MCI) is a clinically recognized condition, often being a prodromal dementia state with a risk of further cognitive decline. While there is currently no definitive diagnostic test for MCI, early identification and intervention are important. Methods To assist clinicians in the diagnosis and treatment of MCI, the ASian Clinical Expert group on Neurocognitive Disorders (ASCEND) convened to identify ongoing gaps in MCI management primarily in Asia, and to discuss the existing body of literature with a view to providing evidence‐based expert recommendations. Results Two novel algorithms and a set of expert recommendations were formulated, addressing the cognitive assessment and clinical diagnosis of MCI, and optimal MCI management approaches. Because many risk factors for cognitive decline are modifiable, the mainstay of intervention comprises a multi‐domain approach involving optimizing metabolic health, mitigating cerebrovascular risk, correcting hearing and vision loss, treating depression, encouraging engagement in cognitive exercises and social connection, and avoiding harmful substances. Digital interventions are becoming increasingly important as tools for cognitive assessment, as well as for cognitive stimulation and to help patients self‐manage and maintain their independence. Pharmacologic approaches for MCI management include medical management of cardiovascular risk, reducing cholinergic burden and the use of drugs known to sedate or affect cognitive function, and evidence‐based medications that have demonstrated benefit specifically in MCI. Conclusions These evidence‐based recommendations are intended to support clinicians, particularly in primary care, to identify MCI and plan an intervention strategy to help slow age‐related cognitive decline.
Background: As people age, they grow more aware of brain health, and interest in keeping the mind sharp has grown alongside anti-aging culture. Neurologic disease is a leading global burden: stroke is the fifth leading cause of death, migraine is the second most burdensome neurological disorder, and more than 57 millio...
Joey R. Gee· Journal of the Osteopathic F...· 0 citations
As the global burden of dementia continues to rise, there is a growing need for accessible, scalable, and precise approaches to cognitive and functional assessment in dementia diagnosis and care. Digital cognitive and functional assessments hold promise in this regard, particularly as disease-modifying treatments incre...
The real-world diagnostic journey, barriers, and management pathways of MCI and mild AD dementia patients in Italy is characterized to characterize the real-world diagnostic journey, barriers, and management pathways of biomarker-based diagnostics in Italy.
S. Ippati, Federico Torelli, Giovanna Zamboni et al.· Journal of Alzheimer's Disea...· 0 citations
Primary care plays a central role in identifying and monitoring mild cognitive impairment (MCI), Alzheimer's disease and other dementias, yet access to suitable cognitive assessment tools remains limited.
To evaluate the feasibility, acceptability, usability and preliminary clinical validity of a digital mul...
W. van den Hurk, Maria M. Johansson, E. Classon et al.· Journal of Alzheimer's Disea...· 0 citations
BackgroundSubjective cognitive decline (SCD) and mild cognitive impairment (MCI) are early clinical markers along the continuum from normal aging to dementia. Both conditions are associated with an elevated risk of progression to Alzheimer's disease and related dementias. With SCD affecting up to 25% and MCI up to 25.2...
Cynthia Zou, Ana-Sophia Chung, Milly Tadigiri et al.· Journal of Alzheimer's Disea...· 0 citations
Abstract Background Mild Cognitive Impairment (MCI) represents a high-risk stage for dementia. Pharmacological treatments for MCI have demonstrated limited efficacy and are frequently associated with adverse effects. Despite recent approvals of Donanemab and Lecanemab, their high cost, complex use, and serious side eff...
D. Kim, Eunkyung Kwan, Y. S. Moon· International Journal of Neu...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.